Antidiabetic therapy effects on bone metabolism and fracture risk

Diabetes, Obesity and Metabolism

Volumn 15, Issue 9, 2013, Pages 784-791

  Montagnani, A ^a   Gonnelli, S ^b  

^a MISERICORDIA HOSPITAL   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Antidiabetic therapy; Bone fracture; Diabetes mellitus; GLP 1 analogue; Incretins; Osteoporosis; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCATION END PRODUCT; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INCRETIN; INSULIN GLARGINE; METFORMIN; OSTEOCALCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; SITAGLIPTIN; SOMATOMEDIN; SULFONYLUREA; VILDAGLIPTIN; WNT PROTEIN;

ANTIDIABETIC ACTIVITY; BONE CELL; BONE METABOLISM; BONE TISSUE; CLINICAL TRIAL; FRACTURE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LIPID METABOLISM; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; RISK; SIGNAL TRANSDUCTION;

ANTIDIABETIC THERAPY; BONE FRACTURE; DIABETES MELLITUS; GLP-1 ANALOGUE; INCRETINS; OSTEOPOROSIS; THIAZOLIDINEDIONES;

AGING; ANIMALS; BONE DENSITY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; FRACTURES, BONE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MALE; METFORMIN; OSTEOCALCIN; OSTEOPOROSIS; PPAR GAMMA; RISK FACTORS; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; WNT PROTEINS;

EID: 84880795348     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12077     Document Type: Review

References (99)

1. Johnell O, Kanis JA, Oden A et al. Mortality after osteoporotic fractures. Osteoporos Int 2004; 15: 38-42.
2. Tosteson AN, Gabriel SE, Grove MR et al. Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int 2001; 12: 1042-1049.
3. Jiang HX, Majumdar SR, Dick DA et al. Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures. J Bone Miner Res 2005; 20: 494-500.
4. Janghorbani M, Van Dam RM, Willett WC et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007; 166: 495-505.
5. Montagnani A, Gonnelli S, Alessandri M, Nuti R. Osteoporosis and risk fracture in patients with diabetes: an update. Aging Clin Exp Res 2011; 23: 84-90.
6. Munoz-Torres M, Jodar E, Escobar-Jimenez F et al. Bone mineral density measured by dual X-ray absorptiometry in Spanish patients with insulin-dependent diabetes mellitus. Calcif Tissue Int 1996; 58: 316-319.
7. Tuominen JT, Impivaara O, Puukka P et al. Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care 1999; 22: 1196-1200.
8. Gallacher SJ, Fenner JA, Fisher BM et al. An evaluation of bone density and turnover in premenopausal women with type 1 diabetes mellitus. Diabet Med 1993; 10: 129-133.
9. Weber G, Beccaria L, deAngelis M et al. Bone mass in young patients with type I diabetes. Bone Miner 1990; 8: 23-30.
10. Alexopoulou O, Jamart J, Devogelaer JP et al. Bone density and markers of bone remodeling in type 1 male diabetic patients. Diabetes Metab 2006; 32: 453-458.
11. Piepkorn B, Kann P, Forst T et al. Bone mineral density and bone metabolism in diabetes mellitus. Horm Metab Res 1997; 29: 584-591.
12. Mastrandrea LD, Wactawski-Wende J, Donahue RP et al. Young women with type 1 diabetes have lower bone mineral density that persists over time. Diabetes Care 2008; 31: 1729-1735.
13. Ivers RQ, Cumming RG, Mitchell P et al. Diabetes and risk of fracture: the blue mountains eye study. Diabetes Care 2001; 24: 1198-1203.
14. Wakasugi M, Wakao R, Tawata M et al. Bone mineral density measured by dual energy X-ray absorptiometry in patients with non-insulin-dependent diabetes mellitus. Bone 1993; 14: 29-33.
15. Van Daele PLA, Stolk RP, Burger H et al. Bone density in non-insulin-dependent diabetes mellitus. Ann Intern Med 1995; 122: 409-414.
16. Schwartz AV, Sellmeyer DE, Ensrud KE et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 2001; 86: 32-38.
17. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type2 diabetes--a meta-analysis. Osteoporos Int 2007; 18: 427-444.
18. Lipscombe LL, Jamal SA, Booth GL et al. The risk of hip fractures in older individuals with diabetes: a population-based study. Diabetes Care 2007; 30: 835-841.
19. Adami S. Bone health in diabetes, considerations for clinical management. Curr Med Res Opin 2009; 25: 1057-1072.
20. Schwartz AV, Hillier TA, Sellmeyer DE et al. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care 2002; 25: 1749-1754.
21. Carnevale V, Romagnoli E, D'Erasmo E. Skeletal involvement in patients with diabetes mellitus. Diabetes Metab Res Rev 2004; 20: 196-204.
22. Lee NK, Sowa H, Hinoi E et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007; 130: 456-469.
23. Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci U S A 2008; 105: 5266-5270.
24. Kanazawa I, Yamaguchi T, Yamamoto M et al. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab 2009; 94: 45-49.
25. Kanazawa I, Yamaguchi T, Yamamoto M et al. Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporos Int 2011; 22: 187-194.
26. Kindblom JM, Ohlsson C, Ljunggren O et al. Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J Bone Miner Res 2009; 24: 785-791.
27. Fernandez-Real JM, Izquierdo M, Ortega F et al. The relationship of serum osteocalcin concentration to insulin secretion, sensitivity, and disposal with hypocaloric diet and resistance training. J Clin Endocrinol Metab 2009; 94: 237-245.
28. Hwang YC, Jeong KJ, Chung AH. Circulating osteocalcin level is associated with improved glucose tolerance, insulin secretion and sensitivity independent of the plasma adiponectin level. Osteoporos Int 2012; 23: 1337-1342.
29. Kanazawa I, Tanaka K, Ogawa N, Yamauchi M, Yamaguchi T, Sugimoto T. Undercarboxylated osteocalcin is positively associated with free testosterone in male patients with type 2 diabetes mellitus. Osteoporos Int 2013; 24: 1115-1119.
30. Mani A, Radhakrishnan J, Wang H et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 2007; 315: 1278-1282.
31. Manolagas SC, Almeida M. Gone with the Wnts: β-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol 2007; 21: 2605-2614.
32. Hoogeboom D, Burgering BM. Should I stay or should I go: β-catenin decides under stress. Biochim Biophys Acta 2009; 1796: 63-74.
33. DeCarolis NA, Wharton KA Jr, Eisch AJ. Which way does the Wnt blow? Exploring the duality of canonical Wnt signaling on cellular aging. Bioessays 2008; 30: 102-106.
34. Jin T. The Wnt signalling pathway and diabetes mellitus. Diabetologia 2008; 51: 1771-1780.
35. Thrailkill KM, Liu L, Wahl EC et al. Bone formation is impaired in a model of type 1 diabetes. Diabetes 2005; 54: 2875-2881.
36. Jehle PM, Jehle DR, Mohan S et al. Serum levels of insulin like growth factor system components and relationship to bone metabolism in type 1 and type 2 diabetes mellitus patients. J Endocrinol 1998; 159: 297-306.
37. Kanazawa I, Yamaguchi T, Sugimoto T. Serum insulin-like growth factor-I is a marker for assessing the severity of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int 2011; 22: 1191-1198.
38. Hernandez CJ, Tang SY, Baumbach BM et al. Trabecular microfracture and the influence of pyridinium and non-enzymatic glycation mediated collagen cross-links. Bone 2005; 37: 825-832.
39. Wang X, Shen X, Li X, Agrawal CM. Age-related changes in the collagen network and toughness of bone. Bone 2002; 31: 1-7.
40. Takagi M, Kasayama S, Yamamoto T et al. Advanced glycation end products stimulate interleukin-6 production by human bone-derived cells. J Bone Miner Res 1997; 12: 439-446.
41. Katayama Y, Akatsu T, Yamamoto M, Kugai N, Nagata N. Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia. J Bone Miner Res 1996; 11: 931-937.
42. Miyata T, Notoya K, Yoshida K et al. Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol 1997; 8: 260-270.
43. Yamamoto T, Ozono K, Miyauchi A et al. Role of advanced glycation end products in adynamic bone disease in patients with diabetic nephropathy. Am J Kidney Dis 2001; 38: S161-164.
44. Sanguineti R, Storace D, Monacelli F, Federici A, Odetti P. Pentosidine effects on human osteoblasts in vitro. Ann N Y Acad Sci 2008; 1126: 166-172.
45. Ogawa N, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M, Sugimoto T. The combination of high glucose and advanced glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs. Horm Metab Res 2007; 39: 871-875.
46. Odetti P, Fogarty J, Sell DR, Monnier VM. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 1992; 41: 153-159.
47. Monnier VM, Sell DR, Nagaraj RH et al. Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes 1992; 41: 36-41.
48. Grandhee SK, Monnier VM. Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J Biol Chem 1991; 266: 11649-11653.
49. Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2008; 93: 1013-1019.
50. Karsenty G. Minireview: transcriptional control of osteoblast differentiation. Endocrinology 2001; 142: 2731-2733.
51. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002; 143: 2376-2384.
52. Akune T, Ohba S, Kamekura S et al. PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004; 113: 846-855.
53. Lecka-Czernik B, Gubrij I, Moerman EJ et al. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARγ2. J Cell Biochem 1999; 74: 357-371.
54. Wongdee K, Charoenphandhu N. Osteoporosis in diabetes mellitus: possible cellular and molecular mechanisms. World J Diabetes 2011; 2: 41-48.
55. Follak N, Klting I, Wolf E, Merk H. Improving metabolic control reverses the histomorphometric and biomechanical abnormalities of an experimentally induced bone deficit in spontaneously diabetic rats. Calcif Tissue Int 2004; 74: 551-560.
56. McNair P, Madsbad S, Christensen M et al. Bone mineral loss in insulin-treated diabetes mellitus: studies on pathogenesis. Acta Endocrinol 1979; 90: 463-472.
57. Vestergaard P, Rejnmark L, Mosekilde L. Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int 2009; 84: 45-55.
58. Schwartz AV, Margolis KL, Sellmeyer DE et al. Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial. Diabetes Care 2012; 35: 1525-1531.
59. Montagnani A, Gonnelli S, Cepollaro C et al. Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: a 1-year longitudinal study. Bone 2003; 32: 427-433.
60. Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 2005; 48: 1292-1299.
61. Monami M, Cresci B, Colombini A et al. Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. Diabetes Care 2008; 31: 199-203.
62. Cortizo AM, Sedlinsky C, McCarthy AD et al. Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture. Eur J Pharmacol 2006; 536: 38-46.
63. Schurman L, McCarthy AD, Sedlinsky C et al. Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells. Exp Clin Endocrinol Diabetes 2008; 116: 333-340.
64. Kahn SE, Haffner S, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
65. Yki-Jarvinen H. Drug therapy: thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
66. Kahn CR, Chen L, Cohen SE. Unraveling the mechanism of action of thiazolidinediones. J Clin Invest 2000; 106: 1305-1307.
67. Beresford JN. Osteogenic stem cells and the stromal system of bone and marrow. Clin Orthop Relat Res 1989; 240: 270-280.
68. Pittenger MF, Mackay AM, Becke SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147.
69. Okuno A, Tamemoto H, Tobe K et al. Troglitazone increases the number of small adipocytes without the change in white adipose tissue in obese Zucker rats. J Clin Invest 1998; 101: 1354-1361.
70. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004; 145: 401-406.
71. Pei L, Tontonoz P. Fat's loss is bone's gain. J Clin Invest 2004; 113: 805-806.
72. Lecka-Czernik B, Ackert-Bicknell C, Adamo ML et al. Activation of peroxisome proliferator-activated receptor γ (PPARγ) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 2007; 148: 903-911.
73. Home PD, Jones NP, Pocock SJ et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med 2007; 24: 626-634.
74. Dormandy JA, Charbonnel B, Eckland D et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
75. Meier C, Kraenzlin ME, Bodmer M et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008; 168: 820-825.
76. Bonds DE, Larson JC, Schwartz AV et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 2006; 91: 3404-3410.
77. Schwartz AV, Sellmeyer DE, Vittinghoff E et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006; 91: 3349-3354.
78. Grey A, Bolland M, Gamble G et al. The peroxisome-proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007; 92: 1305-1310.
79. Rubin GL, Zhao Y, Kalus AM et al. Peroxisome proliferator activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res 2000; 60: 1604-1608.
80. Seto-Young D, Paliou M, Schlosser J et al. Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. J Clin Endocrinol Metab 2005; 90: 6099-6105.
81. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev 2002; 18(Suppl. 2): S10-15.
82. Jiang Y, Jahagirdar BN, Reinhardt RL et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002; 418: 41-49.
83. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009; 180: 32-39.
84. Betteridge DJ. Thiazolidinediones and fracture risk in patients with type 2 diabetes. Diabet Med 2011; 28: 759-771.
85. Douglas IJ, Evans SJ, Pocock S, Smeeth L. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med 2009; 6: e1000154.
86. Clowes J, Khosla S, Eastell R. Potential role of pancreatic and enteric hormones in regulating bone turnover. J Bone Miner Res 2005; 9: 1497-1506.
87. Bollag RJ, Zhong Q, Phillips P et al. Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology 2000; 141: 1228-1235.
88. Zhong Q, Itokawa T, Sridhar S et al. Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am J Physiol Endocrinol Metab 2007; 292: E543-E548.
89. Xie D, Cheng H, Hamrick M et al. Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover. Bone 2005; 37: 759-769.
90. Xie D, Zhong Q, Ding KH et al. Glucose-dependent insulinotropic peptide overexpressing transgenic mice have increased bone mass. Bone 2007; 40: 1352-1360.
91. Yamada C, Yamada Y, Tsukiyama K et al. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology 2008; 149: 574-579.
92. Tsukiyama K, Yamada Y, Yamada C et al. Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. Mol Endocrinol 2006; 20: 1644-1651.
93. Nuche-Berenguer B, Moreno P, Esbrit P et al. Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic and insulin-resistant states. Calcif Tissue Int 2009; 84: 453-461.
94. Nuche-Berenguer B, Moreno P, Portal-Nunez S et al. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states. Regul Pept 2010; 159: 61-66.
95. Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care 2011; 34: 2474-2476.
96. Kyle KA, Willett TL, Baggio LL, Drucker DJ, Grynpa MD. Differential effects of PPAR-g activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice. Endocrinology 2011; 152: 457-467.
97. Bunck MC, Eliasson B, Cornér A et al. Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13: 374-377.
98. Yamagishi S. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. Curr Drug Targets 2011; 12: 2096-2102.
99. Yamagishi S, Matsui T. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes. Curr Pharm Des 2011; 17: 4379-4385.